In this issue:
Half- vs stable-dose conventional synthetic DMARDs
in patients with RA in remission
Which DMARD to use with different biologics in RA
SLE Risk Probability Index assists with SLE diagnosis
Care of patients with early inflammatory arthritis in Wellington
VTE risk with JAK inhibitors
Upadacitinib and adalimumab for psoriatic arthritis
TNF inhibitor dose reduction for axial spondyloarthritis
Vitamin K antagonist anticoagulants increase the risk of OA
Disease activity influences the reclassification of RA into very high cardiovascular risk
Warfarin use and risk of knee and hip replacements
Please login below to download this issue (PDF)